An Open-Label Study to Assess the Long-term Safety of AXS-05 in Subjects With Dementia of the Alzheimer's Type, ADVANCE-2 and ACCORD-2 Extension Study

Stopped Study AXS-05-AD-305 was terminated due to completion of overall program objectives.

Conditions

• Agitation in Patients With Dementia of the Alzheimer's Type
• Alzheimer Disease
• Agitation, Psychomotor

Interventions

• DRUG: AXS-05 (dextromethorphan-bupropion)

Sponsor

Axsome Therapeutics, Inc.